DAWNRAYS PHARMA (02348) announced its interim results for 2025, reporting revenue of approximately 630 million yuan, representing a year-over-year increase of 9.2%. Gross profit reached approximately 314 million yuan, marking a decline of 7.1% compared to the same period last year.

Net profit attributable to owners of the parent company totaled approximately 105 million yuan, reflecting a significant decrease of 78.79% year-over-year. Earnings per share stood at 0.06961 yuan, while the interim dividend per share was set at 0.015 Hong Kong dollars.